drugset / Trial / NCT06132841

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese

NCT06132841

Phase 1 Completed 104 enrolled AstraZeneca Parexel · collab
RandomizedSequentialSingle-blindTreatment

Summary

A study in healthy male and female participants of non-childbearing and childbearing potential who have overweight or obesity

Timeline

Start
2023-11-13
Primary completion
2026-02-03
Completion
2026-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD6234 Small activating RNA (saRNA) Subcutaneous

Indications

No indication recorded.